S Salim*, R Eljim, A Mejait, M Abkari, A Ibrahimi and N Lahmidani

Hepato-Gastroenterology Department, Hassan II University Hospital, Fez, Morocco

*Corresponding Author: S Salim, Hepato-Gastroenterology Department, Hassan II University Hospital, Fez, Morocco.

Received: April 08, 2024; Published: April 25, 2024

Abstract

Systemic treatments employed in oncology, including cytotoxic agents and targeted therapies, often lead to gastrointestinal side effects. The severity of colitis and its potential complications necessitate prompt diagnosis and appropriate management. We present the case of a 70-year-old, he was diagnosed since May 2023 for a dedifferentiated liposarcoma on the 10th left rib put on chemotherapy based on D-Rubicin 90mg; and who presented five days after the first course of treatment a severe bloody diarrhea with haemodynamic instability; the patient benefited from an upper and lower digestive endoscopy having objectified revealed two ulcers with thickened irregular margins and fibrinous background, centered on regenerative areas. Biopsies confirmed subacute colitis with non-specific epithelial abnormalities; doxorubicin was halted, and the patient was kept under clinical surveillance with transfusion and corticosteroid enema with good clinical improvement..

Keywords: Acute Hemorrhagic, Colitis, Doxorubicin, Chemotherapye

References

1. Venkatesh P and Kasi A. “StatPearls”. StatPearls Publishing; Treasure Island (FL) (2023).
2. Bayles CE., et al. “Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology”. Toxicology and Applied Pharmacology 459 (2023): 116362.
3. Lai C., et al. “Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment”. Blood Advances 4 (2023): 529-532.
4. Lewis WD., et al. “Lymphoma: Diagnosis and Treatment”. American Family Physician 1 (2022): 34-41. 
5. Marinello J., et al. “Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives”. International Journal of Molecular Sciences 11 (2020).
6. Wallace KB., et al. “Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy”. Circulation Research 7 (2020): 926-941.
7. Bansal N., et al. “Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors”. Cardiooncology 5 (2019): 18.
8. Perez IE., et al. “Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician”. Clinical Medicine Insights: Cardiology 13 (2019): 1179546819866445. 
9. Ben-Aharon I., et al. “Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity”. Oncologist9 (2017): 985-991. 
10. Lyon AR., et al. “ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)”. European Heart Journal 41 (2022): 4229-4361.
11. Savani M and Skubitz KM. “Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation”. Journal of Pediatric Hematology/Oncology 2 (2019): e94-e96.
12. Cranmer LD., et al. “Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)”. Clinical Cancer Research6 (2023): 1068-1076.
13. American College of Gastroenterology, Patient education and resource centre home page. Common GIsymptoms (2017).

Citation

Citation: S Salim., et al. “Case Report: Acute Hemorrhagic Colitis Following Doxorubicin Chemotherapy". Acta Scientific Gastrointestinal Disorders 7.5 (2024): 09-12.

Copyright

Copyright: © 2024 S Salim., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.